{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-103556","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2023-09-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.985707+00:00","generated_at":"2026-06-10T09:16:18.561985+00:00","sec_items":["1.01","5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Co-founder Dr. Nandabalan resigns from BTAI board; enters 5-year non-compete","bullets":["Dr. Krishnan Nandabalan resigned from board effective Sept 19, 2023; no disagreement with company.","BioXcel entered non-compete with Nandabalan, InveniAI, and Invea: 5-year bar in neuroscience/immuno-oncology; 2-year no-solicit.","Sandeep \"Steve\" Laumas resigned as Class II director and was reappointed Class I to rebalance board classes; board now 6 members.","Non-compete includes $2M liquidated damages for breach by InveniAI or Invea in restricted fields.","BTAI granted right of first negotiation over certain InveniAI assets in restricted fields."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-103556","json":"https://secwatch.observer/filing/0001104659-23-103556.json","markdown":"https://secwatch.observer/filing/0001104659-23-103556.md","text":"https://secwatch.observer/filing/0001104659-23-103556.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923103556/0001104659-23-103556-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923103556/tm2326812d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T09:16:18.561985+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c620c61ad2","claim":"Krishnan Nandabalan resigned as Director at BioXcel Therapeutics, Inc..","evidence_excerpt":"On September 19, 2023, Dr. Nandabalan resigned as a member of the Company’s Board of Directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923103556/0001104659-23-103556-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}